Overnight Health Care – Presented by EMAA – Collins resigns as NIH director

0


Welcome to Tuesday Health Carewhere we keep track of the latest guidelines and news about your health. Register here: thehill.com/newsletter-signup.

To hit the grim milestone of reaching 700,000 COVID-19 deaths nationwide, the National Cathedral plans to ring its bell 700 times for about 70 minutes to commemorate the deceased.

Francis Collins, who served under Presidents Biden, Trump, and Obama, is stepping down as director of the National Institutes of Health.

For The Hill we are Peter Sullivan ([email protected]), Nathaniel Weixel ([email protected]) and Justine Coleman ([email protected]). Write to us with tips and feedback and follow us on Twitter: @ PeterSullivan4, @NateWeixel and @ JustineColeman8.

Let’s begin.

Collins receives bipartisan praise for being awarded by NIH. resigns

It’s the end of an era at the National Institutes of Health.

Francis Collins, the NIH director, announced Tuesday that he is stepping down after nearly 30 years in the agency.

“It has been an incredible privilege to lead this great agency for more than a decade,” said Collins in a statement.

“I love this agency and its employees so much that the decision to resign was a difficult decision that I made in close consultation with my wife, Diane Baker and my family,” he said, adding that he was “proud of.” everything we “did it.”

However, Collins said that he believed that “no single person should stay in this position for too long and that it is time to hire a new scientist to lead the NIH into the future.”

Collins, 71, has served as the head of the NIH for more than 12 years and the agency’s first director to serve under three presidents.

President Biden will appoint a new director who will have to be confirmed by a Senate vote.

“Millions of people will never know that Dr. Collins saved her life, “Biden said in a statement on Tuesday, calling him” one of the most important scientists of our time. “

Big picture: Collins managed the rare feat of earning high praise from both sides. “DR. Collins is the only NIH president-appointed director serving more than one government – a testament to the trust and respect he has earned on both sides of the aisle,” said Sen. Roy BluntRoy Dean BluntEx Rep. Akin dies aged 74 Missouri Republicans ponder Senate race launches statewide complaint against Democratic spending bill Roy Blunt has helped forge and strengthen common bonds between Australia and America MORE (R-Mo.).

Read more here.

A MESSAGE FROM EMAA

After more than 20 years of use, evidence shows that drug abortion is safe and effective. It is time for the FDA to follow science and lift outdated restrictions on abortion drugs.

J&J is asking for an emergency permit for the coronavirus vaccine booster

Johnson & Johnson announced Tuesday that it has asked the Food and Drug Administration (FDA) to issue an emergency license to booster its COVID-19 vaccine for anyone aged 18 and over.

In a statement, the company said it based its application on the results of a late-stage clinical trial that found that a booster dose of its single vaccine given 56 days after the first dose provided 94 percent protection against symptomatic COVID- 19 offers, and 100 percent protection against serious and critical illness at least 14 days after the second dose.

The move comes as the Biden administration intensifies its campaign to give booster doses.

The US began adopting booster cans late last month. According to data from the Centers for Disease Control and Prevention, more than 5.7 million people have received a booster dose.

The FDA has already approved booster syringes for Pfizer’s vaccine for people aged 65 and over and those at high risk of serious illness.

Moderna has also started submitting data to the agency on a booster dose of its vaccine.

Coming soon, FDA meeting: The FDA’s Vaccine Advisory Panel will meet later this month to discuss booster doses of Moderna and J & J’s vaccine. Both vaccines are currently approved for adults aged 18 and over.

Read more here.

ANOTHER FDA INQUIRY: ASTRAZENECA’S COVID-19 PREVENTATION TREATMENT

AstraZeneca also filed an emergency approval application on Tuesday for an antibody drug designed to help prevent symptomatic COVID-19.

Antibody therapy, named AZD7442, offers a “statistically significant reduction” in the risk of developing COVID-19 and could provide further protection for vulnerable populations, including the immunocompromised, against the deadly disease, the company said in a statement.

In its application to the Food and Drug Administration (FDA), AstraZeneca cited data from a study that showed the drug was 77 percent effective in thwarting symptomatic COVID-19. More than three quarters of the tested population were immunocompromised or had other comorbidities that are associated with a serious illness.

Meaning: If the FDA grants emergency approval for the drug, it will be the first long-acting antibody cocktail to receive such approval for COVID-19 prevention, the company said.

Mene Pangalos, head of biopharmaceutical research at AstraZeneca, said the antibody combination will help people who do not have a full immune response to COVID-19 vaccines and need more to adequately prevent infections.

“With this first global regulatory filing, we are one step closer to providing an additional option to protect against COVID-19 alongside vaccines,” Pangalos said in the press release.

Read more here.

COVID-19 Vaccines May Save the Lives of 39,000 Seniors in the US: HHS Study

According to estimates from a Department of Health (HHS) report released Tuesday, COVID-19 vaccines may have saved the lives of tens of thousands of seniors across the country earlier this year.

The study suggests that COVID-19 vaccinations could have prevented approximately 265,000 infections, 107,000 hospital stays, and 39,000 deaths among Medicare recipients in the first five months of 2021.

Specifically, researchers found that the vaccines may have stopped 5,600 deaths among Medicare recipients in nursing homes – a population that was badly affected by the pandemic before vaccines.

The vaccination rate among seniors rose from 1 percent to 80 percent in these five months. Weekly COVID-19 hospital admissions and deaths among Medicare beneficiaries fell 11 to 12 percent for every 10 percent increase in vaccination rates in the county.

All races and ethnic groups, as well as the 48 states included in the study, estimated a decrease in cases, hospital admissions and deaths related to increases in vaccination rates. Texas and Hawaii were excluded from the analysis because of “data reporting limitations”.

What this means: The HHS report signals the vaccines’ effectiveness in averting possible deaths in the elderly, after the majority of pre-shot deaths occurred in people 65 and older who were eligible for Medicare.

HHS secretary Xavier BecerraXavier BecerraFDA Approves New Rapid COVID-19 Test, Says Capacity Will Double said the report underscores the Biden government’s efforts to vaccinate the country and prioritize elderly populations, and shows that these doses “save lives, prevent hospital stays and reduce infections”.

Read more here.

A MESSAGE FROM EMAA

After more than 20 years of use, evidence shows that drug abortion is safe and effective. It is time for the FDA to follow science and lift outdated restrictions on abortion drugs.

STUDY: ANXIETY AND DEPRESSION IN ADULTS INCREASING DURING THE WINTER COVID-19 EMERGENCY

Another study published Tuesday found that the incidence of symptoms of anxiety and depression in American adults increased during the winter Covid-19 surge, showing the pandemic’s impact on the country’s mental health.

Research by the Centers for Disease Control and Prevention, which spanned August 2020 to June 2021, found that the incidence of anxiety and depression peaked between December 2020 and January 2021, when the COVID-19 cases during the holiday season shot to new heights.

According to the numbers: On average, the frequency of anxiety symptoms increased 13 percent from August to December 2020, before decreasing by 26.8 percent by June 2021. Likewise, the incidence of symptoms of depression increased 14.8 percent before decreasing 24.8 percent over the same time periods.

The rise and fall in the incidence of symptoms of anxiety and depression “mirrored” trends in the weekly number of new COVID-19 cases at the national level, suggesting that the increases may have played a role.

Despite the decline, researchers found that the incidence of anxiety and depression was still “significantly” higher than before the pandemic.

Reservation: The study does not include data before August 2020 and after June 2021, so it is unclear how anxiety and depression levels became the dominant strain in the United States compared to when the pandemic began and when the Delta variant

Read more here.

WHAT WE READ

  • Vaccines are there. The school is open. Some parents are still torturing themselves (The Associated Press)

  • Covid-19 cases are falling but remain high in children. This is what the US must do to stop the surge (CNN)

  • A better name for booster shots (The Atlantic)

STATE BY STATE

  • The summer surge in Covid-19 put telemedicine to the test in a rural intensive care unit (Stat News)

  • COVID spike puts Alaska’s health system on the brink (The Associated Press)

  • SC employees are “ready for war” with DHEC if the health authorities do not issue special permits for vaccines (post and courier).

OP EDS IN THE HILL

That’s it for today, thanks for reading. Check out The Hill’s health page for the latest news and coverage. Until Wednesday.



Leave A Reply

Your email address will not be published.